June 30, 2020 / 12:05 PM / 12 days ago

BRIEF-Exelixis Announces Initiation Of Phase 3 Pivotal Trial For Previously Treated Metastatic Castration-Resistant Prostate Cancer

June 30 (Reuters) - Exelixis Inc:

* EXELIXIS ANNOUNCES INITIATION OF CONTACT-02 PHASE 3 PIVOTAL TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PREVIOUSLY TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

* EXELIXIS INC - CONTACT-02 IS SECOND OF THREE PHASE 3 PIVOTAL TRIALS THAT ARE PART OF A CLINICAL COLLABORATION WITH ROCHE

* EXELIXIS INC - INITIATION FOLLOWS POSITIVE RESULTS FROM COHORT 6 OF PHASE 1B COSMIC-021 TRIAL

* EXELIXIS INC - CO-PRIMARY ENDPOINTS OF CONTACT-02 TRIAL ARE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below